← Leaderboards
Nitin Roper
Division Of Basic Sciences - Nci
$0
Attributed
$0
Total exposure
0
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding mix
By agency
—
By mechanism
—
Top collaborators
No co-investigators on record.
Most similar at Division Of Basic Sciences - Nci
Same institution · by research overlap
Others in their field
Top investigators on “Neuroendocrine Tumors”
- David Macpherson · Carnegie Institution Of Washington, D.C.$11,499,752
- Julien Sage · University Of California Santa Cruz$10,217,874
- David J. Kwiatkowski · Brigham And Women'S Hospital$8,874,846
- James A Decaprio · Dana-Farber Cancer Institute$7,914,342
- Himisha Beltran · Dana-Farber Cancer Inst$7,515,798
- Michael King Schultz · Viewpoint Molecular Targeting, Inc.$6,896,677
Research focus
Neuroendocrine TumorsBiologicalImmunotherapyInterestPre-Clinical ModelImmunologicsEpigenetic ProcessResponseTumorPredicting ResponseCheckpoint InhibitionNeuroendocrine CancerTherapeutic StudiesOrganoidsNotch ProteinTreatment ResponseSignal TransductionPrognosisAdrenocortical CarcinomaTumor HeterogeneityNovel TherapeuticsCancer Cell LineFutureClinic
Grant awards (11)
Epigenetic and immunologic aspects of neuroendocrine cancers$1,638,645
ZIA · FY2025 · CA · contact PI
Developing ACC patient-derived organoids to identify therapeutic vulnerabilities$182,071
ZIA · FY2025 · CA · contact PI
Epigenetic and immunologic aspects of neuroendocrine cancers$1,295,687
ZIA · FY2024 · CA · contact PI
Developing ACC patient-derived organoids to identify therapeutic vulnerabilities$143,965
ZIA · FY2024 · CA · contact PI
Epigenetic and immunologic aspects of neuroendocrine cancers$1,140,320
ZIA · FY2023 · CA · contact PI
Developing ACC patient-derived organoids to identify therapeutic vulnerabilities$126,703
ZIA · FY2023 · CA · contact PI
Epigenetic and immunologic aspects of neuroendocrine cancers$579,811
ZIA · FY2022 · CA · contact PI
Developing ACC patient-derived organoids to identify therapeutic vulnerabilities$64,424
ZIA · FY2022 · CA · contact PI
Epigenetic and immunologic aspects of neuroendocrine cancers$537,880
ZIA · FY2021 · CA · contact PI
Developing ACC patient-derived organoids to identify therapeutic vulnerabilities$134,470
ZIA · FY2021 · CA · contact PI
Epigenetic and immunologic aspects of high-grade neuroendocrine cancers$604,110
ZIA · FY2020 · CA · contact PI